A panel of six IgG monoclonal antibodies (MAbs) was produced by immunizing mice with a 22 amino acid synthetic peptide, designated V3.3, of the third variable region of feline immunodeficiency virus (FIV) envelope glycoprotein. This peptide is known to induce neutralizing antibodies in cats. In ELISA all MAbs reacted with purified SDS-disrupted FIV and in flow cytometry all MAbs stained permeated, persistently infected FL4 cells but not unfixed FL4 cells; this indicated that the MAbs recognize essentially cryptic epitopes of the gp100 V3 loop. By direct ELISA using partially overlapping synthetic peptides and by competition binding studies, the anti-V3.3 MAbs were shown to detect at least four distinct epitopes, two located in the amino-terminal half and two in the carboxy-terminal half of the sequence. When tested for neutralizing activity by the syncytium inhibition assay in Crandell feline kidney cells, all anti-V3.3 MAbs neutralized FIV at high dilution. However, at low dilution two MAbs exhibited much less neutralizing activity. These results indicate that the V3 region of FIV contains multiple epitopes involved in neutralization.
BaldinottiF.,
MatteucciD.,
MazzettiP.,
GiannelliC.,
BandecchiP.,
TozziniF.,
BendinelliM.1994; Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. Journal of Virology 68:4572–4579
BendinelliM.,
PistelloM.,
LombardiS.,
PoliA.,
GarzelliC.,
MatteucciD.,
Ceccherini-NelliL.,
MalvaldiG.,
TozziniF.1995; Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clinical Microbiology Review 8:87–112
BjörlingE.,
ChiodiF.,
UtterG.,
NorrbyE.1994; Two neutralizing domains in the V3 region in the envelope glycoprotein gp 125 of HIV type 2. Journal of Immunology 152:1952–1959
Bou-HabibD. C.,
RodriquezG.,
OraveczT.,
BermanP. W.,
LussoP.,
NorcrossM. A.1994; Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. Journal of Virology 68:6006–6013
De RondeA.,
StamJ. G.,
BoersP.,
LangedijkH.,
MeloenR.,
HesselinkW.,
KeldermansL. C. E. J. M.,
van VlietA.,
VerschoorE. J.,
HorzinekM. C.,
EgberinkH. F.1994; Antibody response in cats to the envelope proteins of feline immunodeficiency virus: identification of an immunodominant neutralization domain. Virology 198:257–264
EarlP. L.,
BroderC. C.,
LongD.,
LeeS. A.,
PetersonJ.,
ChakrabartiS.,
DomsR. W.,
MossB.1994; Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. Journal of Virology 68:3015–3026
EgberinkH.,
KeldermansL.,
SchuurmanN.,
StamJ.,
HesselinkW.,
van VlietA.,
VerschoorE.,
HorzinekM.,
de RondeA.1994; Monoclonal antibodies to immunodominant and neutralizing domains of the envelope surface protein of feline immunodeficiency virus. Journal of General Virology 75:889–893
KliksS. C.,
ShiodaT.,
HaidwoodN. L.,
LevyJ. A.1993; V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences, USA 90:11518–11522
LombardiS.,
GarzelliC.,
La RosaC.,
ZaccaroL.,
SpecterS.,
MalvaldiG.,
TozziniF.,
EspositoF.,
BendinelliM.1993; Identification of a linear neutralization site within the third variable region of feline immunodeficiency virus envelope. Journal of Virology 67:4742–4749
LombardiS.,
GarzelliC.,
PistelloM.,
MassiC.,
MatteucciD.,
BaldinottiF.,
CammarotaG.,
Da PratoL.,
BandecchiP.,
TozziniF.,
BendinelliM.1994a; A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. Journal of Virology 68:8374–8379
MontefioriD. C.,
RobinsonW. E.,
HirschV. M.,
ModlizsewskiA.,
MitchellW. M.,
JohnsonP. R.1990; Antibody dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. Journal of Virology 64:113–119
MontelaroR. C.,
LohreyN.,
ParekhB.,
BlakeneyE. W.,
IsselC. J.1982; Isolation and comparative biochemical properties of the major internal polypeptides of equine infectious anemia virus. Journal of Virology 42:1029–1038
MorikawaS.,
LutzH.,
AubertA.,
BishopD. H. L.1991; Identification of conserved and variable regions in the envelope glycoprotein sequences of two feline immunodeficiency viruses isolated in Zurich, Switzerland. Virus Research 21:53–63
PancinoG.,
ChappeyC.,
SaurinW.,
SonigoP.1993a; B epitopes and selection pressures in feline immunodeficiency vims envelope glycoproteins. Journal of Virology 67:664–672
PhillipsT. R.,
TalbotR. L.,
LamontC.,
MuirS.,
LovelaceK.,
ElderJ. H.1990; Comparison of two host cell range variants of feline immunodeficiency virus. Journal of Virology 64:4605–4613
RigbyM. A.,
HolmesE. C.,
PistelloM.,
MackayA.,
Leigh BrownA. J.,
NeilJ. C.1993; Evolution of structural proteins of feline immunodeficiency virus: molecular epidemiology and evidence of selection for change. Journal of General Virology 74:425–136
RobinsonW. E.,
MontefioriD. C.,
MitchellW. M.,
PrinceA. M.,
AlreH. J.,
DreesmanG. R.,
EichbergJ. W.1989; Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proceedings of the National Academy of Sciences, USA 86:4710–4714
SeligmanS. J.1994; Serial deletion mapping by competition ELISA assay: characterization of a linear epitope in the V3 loop of HIV-1. AIDS Research and Human Retroviruses 10:149–156
SiebelinkK. H. J.,
ChuI.-H.,
RimmelzwaanG. F.,
WeijerK.,
OsterhausA. D. M. E.,
BoschM. L.1992; Isolation and partial characterization of infectious molecular clones of feline immunodeficiency virus obtained directly from bone marrow DNA of a naturally infected cat. Journal of Virology 66:1091–1097
SiebelinkK. H. J.,
RimmelzwaanG. F.,
BoschM. L.,
MeloenR. H.,
OsterhausA. D. M. E.1993; A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization. Journal of Virology 67:2202–2208
SiebelinkK. H. J.,
BoshM. L.,
RimmelzwaanG. F.,
MeloenR. H.,
OsterhausA. D. M. E.1994; Two different mutations in the envelope protein of feline immunodeficiency virus allow the virus to escape from neutralization by feline serum antibodies. Veterinary Immunology and Immunopathology (in press)
TalbotR. L.,
SpargerE. E.,
LovelaceK. M.,
FitchW. M.,
PedersenN. C.,
LucrwP. A.,
ElderJ. H.1989; Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 86:5743–5747
YamamotoJ. K.,
SpargerE.,
HoE. W.,
AndersenP. R.,
O’ConnorT. P.,
MandellC. P.,
LowenstineL.,
MunnR.,
PedersenN. C.1988; Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. American Journal of Veterinary Research 49:1246–1258
YamamotoJ. K.,
AcleyC. D.,
ZochlinskiH.,
LouieH.,
PembrokeE.,
TortenM.,
HansenH.,
MunnR.,
OkudaT.1991; Development of IL-2-independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines. Intervirology 32:361–375
White-ScharfM. E.,
PottsB. J.,
SmithL. M.,
SokolowskiK. A.,
RuscheJ. M.,
SilverS.1993; Broadly neutralizing monoclonal antibodies in the V3 region of HIV-1 can be elicited by peptide immunization. Virology 192:197–206
WolfT. F.,
NaraP. L.,
GoudsmitJ.1993; Genotypic and phenotypic variation of HIV: impact on AIDS pathogenesis and vaccination. Chemical Immunology 56:1–33